Overweight/obesity in young adulthood interacts with aspects of EBV infection in MS etiology

Anna Karin Hedström, MD, PhD, Nicole Brenner, PhD, Julia Butt, PhD, Jan Hillert, MD, PhD, Tim Waterboer, PhD, Tomas Olsson, MD, PhD,* and Lars Alfredsson, PhD*

Correspondence
Dr. Hedström
anna.hedstrom@ki.se

Neurol Neuroimmunol Neuroinflamm 2021;8:e912. doi:10.1212/NXI.0000000000000912

Abstract

Objective

Because obesity affects the cellular immune response to infections, we aimed to investigate whether high body mass index (BMI) in young adulthood and high Epstein-Barr nuclear antigen 1 (EBNA-1) antibody levels interact with regard to MS risk. We also aimed at exploring potential 3-way interactions between BMI at age 20 years, aspects of Epstein-Barr virus (EBV) infection (high EBNA-1 antibody levels and infectious mononucleosis [IM] history, respectively) and the human leukocyte antigen (*HLA*)-*DRB1*15:01* allele.

Methods

Using Swedish population-based case-control studies (5,460 cases and 7,275 controls), we assessed MS risk in relation to interactions between overweight/obesity at age 20 years, IM history, EBNA-1 levels, and *HLA-DRB1*15:01* status by calculating ORs with 95% CIs using logistic regression. Potential interactions were evaluated on the additive scale.

Results

Overweight/obesity, compared with normal weight, interacted significantly with high (>50th percentile) EBNA-1 antibody levels (attributable proportion due to interaction 0.2, 95% CI 0.1–0.4). The strength of the interaction increased with higher category of EBNA-1 antibody levels. Furthermore, 3-way interactions were present between *HLA-DRB1*15:01*, overweight/obesity at age 20 years, and each aspect of EBV infection.

Conclusions

With regard to MS risk, overweight/obesity in young adulthood acts synergistically with both aspects of EBV infection, predominantly among those with a genetic susceptibility to the disease. The obese state both induces a chronic immune-mediated inflammation and affects the cellular immune response to infections, which may contribute to explain our findings.

RELATED ARTICLE

Editorial

Obesity's role in MS

Page e932

*These authors contributed equally to the manuscript.

From the Department of Clinical Neuroscience (A.K.H., J.H., T.O., L.A.), Karolinska Institutet, Stockholm, Sweden; Infections and Cancer Epidemiology (N.B., J.B., T.W.), German Cancer Research Center (DKFZ), Heidelberg; Center for Molecular Medicine (J.H., T.O.), Karolinska Institutet at Karolinska University Hospital, Solna, Sweden; and Institute of Environmental Medicine (L.A.), Karolinska Institutet, Stockholm, Sweden.

Go to [Neurology.org/NN](https://www.neurology.org/NN) for full disclosures. Funding information is provided at the end of the article.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Glossary

BMI = body mass index; **EBV** = Epstein-Barr virus; **EIMS** = Epidemiological Investigation of Multiple Sclerosis; **EIRA** = Epidemiological Investigation of Rheumatoid Arthritis; **EPNA-1** = Epstein-Barr nuclear antigen 1; **GEMS** = Genes and Environment in Multiple Sclerosis; **HLA** = human leukocyte antigen; **IM** = infectious mononucleosis; **MFI** = median fluorescence intensity.

MS is a multifocal inflammatory disease of the CNS with underlying genetic and environmental factors. Variations in the human leukocyte antigen (HLA) region influence susceptibility to MS with the main effect originating from the Class II *DRB1* gene.¹ Environmental and lifestyle factors increasing MS risk include smoking,² low sun exposure,³ low vitamin D status,⁴ high body mass index (BMI),^{5,6} and Epstein-Barr virus (EBV) infection.⁷ High BMI during adolescence and young adulthood, but not at the time of MS onset, has repeatedly been associated with an increased risk of developing MS.^{5,6} The risk increases in a dose-dependent manner.⁶

Elevated Epstein-Barr nuclear antigen 1 (EBNA-1) antibody levels and infectious mononucleosis (IM) history are aspects of EBV infection that seem to represent separate risk factors for MS.⁷ An additive interaction has been observed between high BMI at age 20 years and a history of IM,⁸ but whether a similar interaction occurs between obesity and elevated EBNA-1 antibody levels is unclear.

Because most environmental and lifestyle risk factors for MS seem to act synergistically with the main genetic risk factor for MS, the *HLA-DRB1*15:01* allele,^{7,9} it is also of interest to study both separate and joint effects of these factors.

Using Swedish population-based case-control studies, comprising 5,460 cases and 7,275 controls, we thus aimed to investigate potential 2- and 3-way interactions between BMI at age 20 years, aspects of EBV infection, and presence of *DRB1*15:01*.

Methods

Study design and study subjects

We used 2 Swedish population-based case-control studies on environmental and genetic risk factors for MS: Epidemiological Investigation of Multiple Sclerosis (EIMS) and Genes and Environment in Multiple Sclerosis (GEMS). The study population comprised the general population aged 16–70 years. In EIMS, newly diagnosed cases of MS were recruited from neurology clinics, including all university hospitals in Sweden. Cases were diagnosed by a neurologist according to the 2005 or 2010 McDonald criteria.^{10,11} For each case, we randomly selected 2 controls from the national population register, frequency matched by age in 5-year age strata, sex, and residential area. The participants were included between April 2005 and June 2015.

In GEMS, we identified prevalent cases of MS from the Swedish National MS Registry.¹² All cases in both studies fulfilled the 2005 or 2010 McDonald criteria.^{10,11} One control for each case was selected in the same manner as in EIMS. All participants were recruited between November 2009 and November 2011.

To increase the number of controls, we also used controls from the Epidemiological Investigation of Rheumatoid Arthritis (EIRA), which is a population-based case-control study with incident cases of rheumatoid arthritis, designed in the same manner as EIMS, using a similar study population in southern and middle parts of Sweden. The EIRA controls were not matched on age, sex, or residential area to MS cases in either EIMS or GEMS. The study has been described in detail elsewhere.¹³

Data collection

We used a standardized questionnaire to collect information regarding environmental exposures and lifestyle factors. The response rate was 93% for cases and 73% for controls in EIMS, 82% for cases and 66% for controls in GEMS, and 75% for controls in EIRA.

In all studies, participants were asked whether they had ever had IM, and if yes, at what age the infection occurred. Those who were unsure regarding IM history were excluded. For each case in EIMS and GEMS, the clinical onset of disease was defined as the index year. The corresponding controls were given the same index year. IM history was considered before the index year and was recorded as either reported infection or no infection.

Self-reported information was obtained regarding current body height and body weight at age 20 years. Subjects younger than 20 years at the index year were excluded. Using current height, we calculated BMI at age 20 years by dividing weight in kilograms by height in meters squared.

All participants were asked to provide a blood sample and those who did not donate blood were excluded from the main analysis. The number of study subjects in each study is presented in table 1.

Potential confounding variables

Ancestry was dichotomized into Swedish or non-Swedish. Educational level was categorized into no postsecondary education, postsecondary education, or university degree. Based on 3 questions about exposure to ultraviolet radiation where each

Table 1 Number of cases and controls included in the study

Study	Included in the study	Disease onset 20 y or older	Data on BMI at age 20 y and IM history	Data on HLA genotype. Data set for analysis	Data on EBNA-1 antibody levels. Data set for analysis
EIMS					
Cases	2,880	2,740	2,309	1,729	1,681
Controls	6,122	5,766	4,851	2,494	2,114
GEMS					
Cases	6,156	5,588	4,385	3,731	3,139
Controls	5,408	4,893	3,987	2,941	2,889
EIRA					
Controls	5,935	5,892	4,907	1,840	—
Total					
Cases	9,036	8,328	6,694	5,460	4,820
Controls	17,465	15,555	13,745	7,275	5,003

Abbreviations: BMI = body mass index; EIMS = Epidemiological Investigation of Multiple Sclerosis; EIRA = Epidemiological Investigation of Rheumatoid Arthritis; EPNA-1 = Epstein-Barr nuclear antigen 1; GEMS = Genes and Environment in Multiple Sclerosis; HLA = human leukocyte antigen; IM = infectious mononucleosis.

answer alternative was given a number ranging from 1 (the lowest exposure) to 4 (the highest exposure), we constructed an index by adding the numbers together and thus acquired a value between 3 and 12.¹⁴ Sun exposure was then dichotomized based on the 25th percentile among controls. Smokers were dichotomized into ever or never smokers. Exposure to passive smoking at home or at work on a daily basis was dichotomized into ever or never exposed. Alcohol consumption was categorized into the following subgroups based on the amount of alcohol intake per week: low consumption (<50 g/wk for women and <100 g/wk for men), moderate consumption (50–112 g/wk for women and 100–168 g/wk for men), and high consumption (>112 g/wk for women and >168 g/wk for men). The cutoffs were the same as those used by Statistics Sweden, a government agency that produces official statistics.

Standard protocol approvals, registrations, and patient consents

Ethical approval for both EIMS and GEMS was obtained from the Regional Ethical Review Board at Karolinska Institutet. All participants gave their written informed consent.

Genotyping and measurement of EBNA-1 antibody levels

In EIMS and GEMS, *HLA-DRB1* and *HLA-A* alleles were determined at 4-digit resolution. Genotyping was performed on the MS replication chip,¹⁵ which is based on an Illumina exome chip, and HLA was then imputed with HLA*IMP:02.¹⁶ In EIRA, *HLA-DRB1* genotypes were obtained as previously described.¹³ In EIMS and GEMS, we used multiplex serology to detect immunoglobulin G antibodies against the EBNA-1 peptide segment (aa 385–420),^{17,18} which has been identified as the primary

EBNA-1 fragment associated with MS risk.¹⁹ Dual-laser flow-based detection was used to quantify the antibodies in median fluorescence intensity (MFI) units. We dichotomized EBNA-1 antibody levels based on the median seroreactivity among controls (5,620 MFI) into groups with high and low EBNA-1 antibody levels.⁷ To study whether the potential interaction between obesity at age 20 years and high EBNA-1 antibody levels was affected by increasing EBNA-1 levels, we also divided the participants into 4 groups based on the seroreactivity among controls at the 50th, 75th, and 95th percentiles.

Statistical analysis

All analyses were adjusted for study, age, sex, residential area, ancestry, smoking, and when appropriate for *A*02:01*, *DRB1*15:01*, and IM history. Adjustments were also made for educational level, sun exposure habits, passive smoking, and alcohol consumption, but these factors had minor influence on the results and were not retained in the final analyses.

Subjects characterized by BMI at age 20 years, EBNA-1 and IM status were compared with regard to MS risk, by calculating ORs with 95% CIs using unconditional logistic regression models.²⁰ Potential interactions were analyzed using departure from additivity of effects as criterion of interaction. Synergistic effects between overweight/obesity at age 20 years and each aspect of EBV infection were evaluated by calculating the attributable proportion due to interaction and relative excess risk due to interaction together with 95% CI.^{21,22} Superadditive associations between overweight/obesity at age 20 years, *HLA-DRB1*15*, and a history of IM (or high EBNA-1 antibody levels) were calculated by comparing the joint effect of the 3 risk factors to the situation when each one acts

Table 2 Characteristics of cases and controls, overall and by study

	Overall		EIMS		GEMS		EIRA
	Cases	Controls	Cases	Controls	Cases	Controls	Controls
Women, n (%)	4,022 (74)	5,520 (76)	1,263 (73)	1,892 (76)	2,759 (74)	2,287 (78)	1,341 (73)
Men, n (%)	1,438 (26)	1,755 (24)	466 (27)	602 (24)	972 (26)	654 (22)	499 (27)
Swedish origin, n (%)	4,454 (82)	5,949 (82)	1,385 (80)	1,929 (77)	3,069 (82)	2,436 (83)	1,584 (86)
BMI at age 20 y, kg/m ² , mean (SD)	22.0 (3.5)	21.6 (3.0)	22.6 (3.8)	21.8 (3.1)	21.7 (3.3)	21.5 (2.9)	21.5 (2.8)
BMI ≥25 kg/m ² , n (%)	719 (13)	686 (9.4)	304 (18)	265 (11)	415 (11)	362 (8.5)	170 (9.2)
A history of IM, n (%)	877 (16)	616 (8.5)	330 (19)	267 (11)	547 (15)	223 (7.6)	126 (6.9)
Ever smoking, n (%)	3,132 (57)	3,688 (51)	934 (54)	1,138 (46)	2,198 (59)	1,466 (50)	1,084 (59)
HLA-DRB1*15:01, n (%)	3,145 (58)	2,069 (28)	955 (55)	688 (28)	2,190 (59)	866 (29)	515 (28)
HLA-A*02:01, n (%)	2,355 (43)	2,986 (55)	719 (42)	1,354 (54)	1,636 (44)	1,632 (55)	—
Median EBNA-1 IgG (MFI)	7,828	5,601	7,807	5,448	7,855	5,699	—
Total	5,460	7,275	1,729	2,494	3,731	2,941	1,840

Abbreviations: BMI = body mass index; EIMS = Epidemiological Investigation of Multiple Sclerosis; EIRA = Epidemiological Investigation of Rheumatoid Arthritis; EPNA-1 = Epstein-Barr nuclear antigen 1; GEMS = Genes and Environment in Multiple Sclerosis; HLA = human leukocyte antigen; IgG = immunoglobulin G; IM = infectious mononucleosis; MFI = median fluorescence intensity.

separately, using the total relative excess risk due to interaction.¹⁸

As sensitivity analyses, we performed the interaction analyses stratified by study. We also conducted all analyses restricted to include subjects with data on HLA alleles as well as anti-EBNA-1 antibody levels. These analyses were further adjusted for *DRB1*15:01* when appropriate and for the following alleles from other HLA regions that have been shown to influence MS risk independently of *DRB1*15:01* status¹: *DRB1*03:01*, *DRB1*13:03*, *DRB1*08:01*, *B*44:02*, *B38:01*, *B44:02*, *DQA1*01:01*, *DQB1*03:02*, and *DQB1*03:01*.¹ Homozygote correction was made for *DRB1*15:01*, *DRB1*03:01*, and *A*02:01*. All analyses were conducted using Statistical Analysis System version 9.4.

Data availability

Anonymized data will be shared by request from any qualified investigator who wants to analyze questions that are related to the published article.

Results

Among the cases, the mean age at disease onset was 33.7 (SD 10.4) years. The majority of cases in EIMS were recruited within 1 year after the diagnosis, and the questionnaires were completed after a median of 2.0 years following MS onset. In GEMS, the median duration from disease onset to study inclusion was 18.0 (SD 11.7) years. Selected characteristics of cases and controls are presented in table 2. Characteristics were similar between those who

donated blood and those who did not (table e-1, links.lww.com/NXI/A374).

BMI at age 20 years and a history of IM

Overweight/obesity at age 20 years and a history of IM synergistically increased the risk of MS. Overall, IM history among nonoverweight subjects was associated with a 90% increased risk of MS, whereas overweight/obesity at age 20 years (BMI ≥25 kg/m²) with no history of IM was associated with a 40% increased MS risk. Compared with nonoverweight subjects without IM history, the combination of the 2 risk factors increased MS risk 5-fold.

BMI at age 20 years and EBNA-1 status

A similar but less pronounced interaction was observed between BMI at age 20 years and high EBNA-1 antibody levels. The interaction became stronger with increasing category of EBNA-1 antibody levels, using a variety of different cut-points (table 3). Our findings remained significant when subjects with a history of IM were excluded.

DRB1*15 status, BMI at age 20 years, and aspects of EBV infection

With regard to MS risk, 2-way interactions were present between *DRB1*15:01* and overweight/obesity at age 20 years, between *DRB1*15:01* and each aspect of EBV infection, and between overweight/obesity at age 20 years and each aspect of EBV infection (tables 4 and 5).

Furthermore, significant 3-way interactions on the additive scale were observed between *DRB1*15:01*, BMI at age 20 years, and each aspect of EBV infection (IM history and high

Table 3 OR with 95% CI of developing MS for subjects with different combinations of BMI at age 20 years and EBNA-1 antibody levels

	EBNA-1 category	ca/co ^a	OR (95% CI) ^b	OR (95% CI) ^c	AP (95% CI)	RERI (95% CI)
BMI at age 20 y, kg/m²						
<25	<50th percentile	1,004/2,264	1.0 (reference)	1.0 (reference)		
≥25	<50th percentile	135/237	1.3 (1.1–1.7)	1.4 (1.1–1.8)		
<25	≥50th percentile	3,194/2,263	3.1 (2.9–3.5)	2.8 (2.5–3.0)		
≥25	≥50th percentile	487/239	4.7 (3.9–5.5)	4.1 (3.4–4.8)	0.2 (0.1 to 0.4)	1.4 (1.1 to 1.8)
BMI at age 20 y, kg/m²						
<25	<50th percentile	1,004/2,264	1.0 (reference)	1.0 (reference)		
≥25	<50th percentile	135/237	1.5 (1.1–1.7)	1.5 (1.1–1.8)		
<25	50th–75th percentile	1,198/1,130	2.4 (2.2–2.7)	2.1 (1.9–2.4)		
≥25	50th–75th percentile	163/120	3.2 (2.5–4.1)	2.7 (2.1–3.5)	0.02 (–0.3 to 0.3)	0.1 (–0.2 to 0.3)
BMI at age 20 y, kg/m²						
<25	<50th percentile	1,004/2,264	1.0 (reference)	1.0 (reference)		
≥25	<50th percentile	135/237	1.3 (1.0–1.6)	1.4 (1.1–1.8)		
<25	75th–95th percentile	1,481/903	3.7 (3.3–4.1)	3.0 (2.7–3.4)		
≥25	75th–95th percentile	236/98	5.7 (4.4–7.3)	4.6 (3.6–6.0)	0.3 (0.1 to 0.5)	1.5 (1.1 to 2.2)
BMI at age 20 y, kg/m²						
<25	<50th percentile	1,004/2,264	1.0 (reference)	1.0 (reference)		
≥25	<50th percentile	135/237	1.3 (1.1–1.7)	1.4 (1.1–1.8)		
<25	>95th percentile	515/230	4.8 (4.0–5.7)	4.0 (3.3–4.8)		
≥25	>95th percentile	85/21	9.2 (5.7–14.9)	7.3 (4.4–12.0)	0.4 (0.1 to 0.7)	2.8 (0.9 to 6.5)

Abbreviations: AP = attributable proportion due to interaction; BMI = body mass index; EBNA-1 = Epstein-Barr nuclear antigen 1; RERI = relative excess risk due to interaction.

^a Number of exposed cases and controls.

^b Adjusted for study, age, sex, residential area, ancestry, and smoking.

^c Adjusted for study, age, sex, residential area, ancestry, smoking, IM history, *A*02:01*, and *DRB1*15:01*.

EBNA-1 antibody levels, respectively) (tables 4 and 5). The results presented in tables 4 and 5 are illustrated in the figure.

All main findings remained significant when the analyses were stratified by study (EIMS and GEMS). The overall interaction between BMI at age 20 years and high EBNA-1 antibody levels, stratified by study, is presented in table e-2, links.lww.com/NXI/A374. All findings also remained significant when we performed the analyses restricted to subjects with complete data on HLA alleles and EBNA-1 antibody levels (data not shown).

Discussion

According to our findings, overweight/obesity in young adulthood acts synergistically with both a history of IM and high EBNA-1 antibody levels. The effect estimates for the interaction between BMI at age 20 years and EBNA-1

antibody levels became stronger with increasing category of antibody levels. Furthermore, significant 3-way interactions on the additive scale were observed between *DRB1*15:01*, BMI at age 20 years, and each aspect of EBV infection.

Adipose tissue is considered an active endocrine organ that results in a strong proinflammatory environment in subjects with obesity. Inflammatory mediators such as interleukin 6, C-reactive protein, and tumor necrosis factor alpha significantly correlate with BMI. Obesity has been associated with a decreased number of regulatory T and B subsets, expansion of Th17 cells, and promotion of auto-antibodies, which may lead to breakdown of self-tolerance and promote the onset and progression of autoimmune responses.^{23–25} Obesity contributes to the development of a number of inflammatory and autoimmune diseases, including MS.^{26,27} Obesity also results in a state of

Table 4 OR with 95% CI of developing MS for subjects with different combinations of *DRB1*15:01* status, BMI at age 20 years, and IM history

BMI at age 20 y, kg/m ²	A history of IM	<i>DRB1*15:01</i>	ca/co ^a	OR (95% CI) ^b	RERI (95% CI)	TotRERI (95% CI)
<25	–	–	1,698/4,305	1.0 (reference)		
≥25	–	–	239/465	1.4 (1.1–1.6)		
<25	+	–	313/399	2.0 (1.7–2.3)		
≥25	+	–	65/37	4.5 (2.9–7.0)	2.1 (0.5–3.7)	
<25	–	+	2,313/1,715	3.4 (3.1–3.7)		
≥25	–	+	333/174	4.8 (3.9–5.9)	1.5 (0.3–2.6)	
<25	+	+	417/170	6.4 (5.2–7.8)	2.4 (1.0–3.8)	
≥25	+	+	82/10	22.2 (10.7–43.6)		15.4 (0.8–30.1)

Abbreviations: BMI = body mass index; EPNA-1 = Epstein-Barr nuclear antigen 1; RERI = relative excess risk due to interaction; TotRERI = total relative excess risk due to interaction; controls from EIRA were included.

^a Number of exposed cases and controls.

^b Adjusted for study, age, sex, residential area, ancestry, and smoking.

immunodeficiency, including altered lymphocyte functionality, rendering obese people more susceptible to infections.²⁸ Immunodeficiency due to obesity may thus alter immune responses to pathogens and increase the risk of an inflammatory response directed at self-antigens. Several environmental factors that predispose to MS, including both high BMI and EBV infection, seem to act long before the clinical onset of the disease. This suggests a sensitive period for lifestyle and environmental factors in MS or may reflect the existence of a prodromal phase for the disease.

Both EIMS and GEMS, as well as EIRA, retrospectively gathered information regarding environmental and lifestyle factors. EIMS included incident cases to minimize

recall bias, whereas GEMS was based on prevalent MS cases and recall bias may therefore be more substantial in this study. However, a validation study among women in the Nurses' Health Study found high correlations between recalled and measured past weight.²⁹

There is a risk of misclassification when dichotomizing subjects into those with and without self-reported IM history. Because infection by other pathogens than EBV may cause an IM-like illness, subjects may unknowingly have had IM. However, this misclassification is not expected to differ between cases and controls. Furthermore, the risk of MS among subjects with a history of IM was in accordance with that of previous studies on past IM and MS risk.³⁰ EBNA-1 antibody levels after MS onset

Table 5 OR with 95% CI of developing MS for subjects with different combinations of *DRB1*15:01* status, BMI at age 20 years, and anti-EBNA-1 antibody levels

BMI at age 20 y, kg/m ²	High EBNA-1 antibody levels	<i>DRB1*15:01</i>	ca/co ^a	OR (95% CI) ^b	RERI (95% CI)	TotRERI (95% CI)
<25	–	–	534/1,710	1.0 (reference)		
≥25	–	–	89/186	1.6 (1.2–2.1)		
<25	+	–	1,230/1,511	2.5 (2.2–2.9)		
≥25	+	–	173/162	3.3 (2.6–4.2)	1.2 (0.4–2.1)	
<25	–	+	470/554	2.8 (2.4–3.3)		
≥25	–	+	46/51	3.1 (2.0–4.7)	1.5 (0.3–2.6)	
<25	+	+	1,964/752	8.2 (7.2–9.4)	4.2 (3.4–5.0)	
≥25	+	+	314/77	13.5 (10.3–17.8)		8.6 (5.0–12.1)

Abbreviations: BMI = body mass index; EPNA-1 = Epstein-Barr nuclear antigen 1; RERI = relative excess risk due to interaction; TotRERI = total relative excess risk due to interaction.

^a Number of exposed cases and controls.

^b Adjusted for study, age, sex, residential area, ancestry, smoking, *A*02:01*, and IM history.

Figure OR of developing MS for subjects with different combinations of *DRB1*15:01*, overweight/obesity (>25 kg/m²), and IM history and EBNA-1 status, respectively, compared with unexposed *DRB1*15:01*-negative subjects

Based on data from tables 4 and 5.

were assumed to reflect levels before disease onset. This assumption is supported by findings that EBNA-1 antibody levels become elevated between 15 and 20 years before the clinical onset of MS and thereafter remain constant over time.³¹ Another concern is that the recruitment of cases and controls may introduce selection bias.

Because the Swedish health care system provides equal free of charge access to medical services for all Swedish citizens, most MS cases are referred to neurologic units. In both MS studies, selection bias was minimized by the population-based design. Although there was proportion of nonresponders among the controls, this bias is probably modest because the prevalence of lifestyle factors, such as smoking and socioeconomic status, among controls was consistent with that of the general population.³² Subjects who were excluded due to unknown IM history did not differ with regard to obesity at age 20 years, EBNA-1 antibody levels, or *DRB1*15:01* status compared with those with known IM history. Furthermore, there were no significant

differences with respect to age, sex, BMI at age 20 years, or IM history between those donated blood and those who did not, indicating that selection bias did not take place in this step.

The worldwide prevalence of overweight/obesity during childhood and young adulthood has increased over the last decades and has emerged as a serious public health concern.³³ The increasing MS incidence in some countries may, at least to some extent, be explained by the increasing prevalence of obesity. Overweight and obesity are largely preventable, and intervention efforts need to be high priority to reduce long-term health consequences, including inflammatory diseases such as MS.

In summary, overweight/obesity in young adulthood acts synergistically with both aspects of EBV infection, predominantly among those with a genetic susceptibility to the disease. The obese state both induces a chronic immune-mediated inflammation and affects the cellular immune

response to infections, which may contribute to explain our findings. Our data reinforce the importance of intervention efforts against childhood and adolescent obesity to reduce MS incidence.

Study funding

The study was supported by grants from the Swedish Medical Research Council, the Swedish Research Council for Health, Working Life and Welfare, and the Swedish Brain Foundation. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Disclosure

A.K. Hedström, N. Brenner, and J. Butt report no disclosures. J. Hillert received honoraria for serving on advisory boards for Biogen, Celgene, Sanofi-Genzyme, Merck KGaA, Novartis, and Sandoz and speaker’s fees from Biogen, Novartis, Merck KGaA, Teva, and Sanofi-Genzyme; he has served as PI for projects or received unrestricted research support from, Biogen Idec, Merck KGaA, Novartis, and Sanofi-Genzyme. T. Waterboer reports no disclosures. T. Olsson served on scientific advisory boards and received speaker honoraria Novartis, Merck, Biogen, Merck, and Genzyme; received from Novartis and Biogen; and receives unrestricted MS research support from Novartis, Genzyme, Biogen, Merck, the Swedish Research Council, and the Swedish Brain Foundation. L. Alfredsson received research support from the Swedish Medical Research Council, the Swedish Council for Health, Working Life and Welfare, and the Swedish Brain Foundation and has received speaker honoraria from Biogen Idec and Teva. Go to [Neurology.org/NN](https://www.neurology.org/NN) for full disclosures.

Publication history

Received by *Neurology: Neuroimmunology & Neuroinflammation* April 20, 2020. Accepted in final form September 11, 2020.

Appendix Authors

Name	Location	Contribution
Anna Karin Hedström, MD, PhD	Karolinska Institutet, Stockholm, Sweden	Designed and conceptualized the study; analyzed the data; and drafted the manuscript
Nicole Brenner, PhD	German Cancer Research Center, Heidelberg	Interpreted the data and revised the manuscript
Julia Butt, PhD	German Cancer Research Center, Heidelberg	Interpreted the data and revised the manuscript
Jan Hillert, MD, PhD	Karolinska Institutet, Stockholm, Sweden	Designed and conceptualized the study; interpreted the data; and revised the manuscript
Tim Waterboer, PhD	German Cancer Research Center, Heidelberg	Interpreted the data and revised the manuscript

Appendix (continued)

Name	Location	Contribution
Tomas Olsson, MD, PhD	Karolinska Institutet, Stockholm, Sweden	Designed and conceptualized the study; interpreted the data; and revised the manuscript
Lars Alfredsson, PhD	Karolinska Institutet, Stockholm, Sweden	Designed and conceptualized the study; interpreted the data; and revised the manuscript

References

1. Moutsianas L, Jostins L, Beecham AH, et al. Class II HLA interactions modulate genetic risk for multiple sclerosis. *Nat Genet* 2015;47:1107–1113.

2. Hedström AK. Smoking and its interaction with genetics in MS etiology. *Mult Scler* 2019;25:180–186.

3. Tremlett H, Zhu F, Ascherio A, Munger KL. Sun exposure over the life course and associations with multiple sclerosis. *Neurology* 2018;90:e1191–e1199.

4. Simpson S Jr, der Mei IV, Taylor B. The role of vitamin D in multiple sclerosis: biology and biochemistry, epidemiology and potential roles in treatment. *Med Chem* 2018;14:129–143.

5. Munger KL, Chitnis T, Ascherio A. Body size and risk of MS in two cohorts of US women. *Neurology* 2009;73:1543–1550.

6. Hedström AK, Olsson T, Alfredsson L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. *Mult Scler* 2012;18:1334–1336.

7. Hedström AK, Huang J, Michel A, et al. High anti-EBNA-1 antibody levels and infectious mononucleosis act both independently and synergistically to increase multiple sclerosis risk. *Front Neurol* 2020;10:1368.

8. Hedström AK, Lima Bomfim I, Hillert J, Olsson T, Alfredsson L. Obesity interacts with infectious mononucleosis in risk of multiple sclerosis. *Eur J Neurol* 2015;22:578–e38.

9. Hedström AK, Bomfim IL, Barcellos LF, et al. Interaction between adolescent obesity and HLA risk genes in the development of multiple sclerosis. *Neurology* 2014;82:865–872.

10. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” *Ann Neurol* 2005;58:840–846.

11. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald Criteria. *Ann Neurol* 2011;69:292–302.

12. Hillert J, Stawiarz L. The Swedish MS registry: clinical support tool and scientific resource. *Acta Neurol Scand* 2015;132:11–19.

13. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. *Arthritis Rheum* 2004;50:3085–3092.

14. Bäärnhielm M, Hedström AK, Kockum I, et al. Sunlight is associated with decreased multiple sclerosis risk: no interaction with human leukocyte antigen-DRB1*15. *Eur J Neurol* 2012;19:955–962.

15. International Multiple Sclerosis Genetics Consortium. The multiple sclerosis genomic map: role of peripheral immune cells and resident microglia in susceptibility. *Science* 2019;365:eaav7188.

16. Dilthey A, Leslie S, Moutsianas L, et al. Multi-population classical HLA type imputation. *PLoS Comput Biol* 2013;9:e1002877.

17. Waterboer T, Sehr P, Michael KM, et al. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. *Clin Chem* 2005;51:1845–1853.

18. Tengvall K, Huang J, Hellström C, et al. Molecular mimicry between an octanin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. *Proc Natl Acad Sci USA* 2019;116:16955–16960.

19. Sundqvist E, Sundström P, Lindén M, et al. Epstein-Barr virus and multiple sclerosis: interactions with HLA. *Genes Immun* 2012;13:14–20.

20. Pearce N. Analysis of matched case-control studies. *BMJ* 2016;25:352–i969.

21. Rothman KJ, Greenland S, Lash TL, editors. *Modern Epidemiology*. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.

22. VanderWeele TJ. Sufficient cause interactions and statistical interactions. *Epidemiology* 2009;20:6–13.

23. Subramanian V, Ferrante AW. Obesity, inflammation, and macrophages. *Nestle Nutr Workshop Ser Pediatr Program* 2009;63:151–159.

24. Lumeng CN, Bodzin JL, Deyoung SM, et al. Increased inflammatory properties of adipose tissue macrophages recruited during diet induced obesity. *Diabetes* 2007;56:16–23.

25. Matarese G, Procaccini C, De Rosa V. The intricate interface between immune and metabolic regulation: a role for leptin in the pathogenesis of multiple sclerosis? *J Leukoc Biol* 2008;84:893–899.

26. Procaccini C, Carbone F, Galgani M, et al. Obesity and susceptibility to autoimmune diseases. *Expert Rev Clin Immunol* 2011;7:287–294.

27. Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. *Autoimmun Rev* 2014;13:981–1000.

28. Karlsson EA, Beck MA. The burden of obesity on infectious disease. *Exp Biol Med* 2010;235:1412–1424.

29. Troy LM, Hunter DJ, Manson JE, Colditz GA, Stampfer MJ, Willett WC. The validity of recalled weight among younger women. *Int J Obes Relat Metab Disord* 1995;19:570–572.
30. Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. *PLoS One* 2010;5:e12496.
31. DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelmann JH, Ascherio A. Epstein-Barr virus and multiple sclerosis. Evidence of association from a prospective study with long-term follow-up. *Arch Neurol* 2006;63:839–844.
32. Internet-based information. Available at: scb.se. Accessed February 15, 2013.
33. Abarca-Gomez L, Abdeen ZA, Hamid ZA, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. *Lancet* 2017;390:2627–2642.

Neurology® Neuroimmunology & Neuroinflammation

Overweight/obesity in young adulthood interacts with aspects of EBV infection in MS etiology

Anna Karin Hedström, Nicole Brenner, Julia Butt, et al.
Neurol Neuroimmunol Neuroinflamm 2021;8;
DOI 10.1212/NXI.0000000000000912

This information is current as of December 15, 2020

Updated Information & Services	including high resolution figures, can be found at: http://nn.neurology.org/content/8/1/e912.full.html
References	This article cites 31 articles, 4 of which you can access for free at: http://nn.neurology.org/content/8/1/e912.full.html##ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): Multiple sclerosis http://nn.neurology.org/cgi/collection/multiple_sclerosis
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://nn.neurology.org/misc/about.xhtml#permissions
Reprints	Information about ordering reprints can be found online: http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Online ISSN: 2332-7812.